79,582 Shares in Pfizer Inc. (NYSE:PFE) Bought by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. bought a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, Holdings Channel reports. The fund bought 79,582 shares of the biopharmaceutical company’s stock, valued at approximately $2,303,000.

Other institutional investors also recently modified their holdings of the company. Lazari Capital Management Inc. raised its position in shares of Pfizer by 17.6% in the 3rd quarter. Lazari Capital Management Inc. now owns 22,224 shares of the biopharmaceutical company’s stock valued at $643,000 after acquiring an additional 3,329 shares during the period. Community Trust & Investment Co. raised its holdings in Pfizer by 7.2% in the third quarter. Community Trust & Investment Co. now owns 113,798 shares of the biopharmaceutical company’s stock worth $3,293,000 after purchasing an additional 7,650 shares during the period. Private Advisor Group LLC boosted its position in shares of Pfizer by 15.4% during the third quarter. Private Advisor Group LLC now owns 849,585 shares of the biopharmaceutical company’s stock worth $24,587,000 after purchasing an additional 113,623 shares in the last quarter. Tempus Wealth Planning LLC grew its holdings in shares of Pfizer by 3.4% in the 3rd quarter. Tempus Wealth Planning LLC now owns 18,301 shares of the biopharmaceutical company’s stock valued at $530,000 after buying an additional 604 shares during the period. Finally, Westhampton Capital LLC increased its position in shares of Pfizer by 31.2% in the 3rd quarter. Westhampton Capital LLC now owns 41,678 shares of the biopharmaceutical company’s stock valued at $1,206,000 after buying an additional 9,900 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.3 %

Shares of PFE stock opened at $28.85 on Wednesday. The firm’s fifty day moving average price is $29.07 and its two-hundred day moving average price is $28.48. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54. The firm has a market capitalization of $163.45 billion, a P/E ratio of -480.75, a PEG ratio of 1.02 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter in the previous year, the business earned $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.82%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently -2,800.00%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Thursday, October 3rd. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.